Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1510/icvts.2010.245001A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline.
Korean J Radiol
January 2025
Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus.
View Article and Find Full Text PDFUltrasound localization microscopy in the diagnosis of breast tumors and prediction of relevant histologic biomarkers associated with prognosis in humans: the protocol for a prospective, multicenter study.
BMC Med Imaging
January 2025
Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Background: Benign and malignant breast tumors differ in their microvasculature morphology and distribution. Histologic biomarkers of malignant breast tumors are also correlated with the microvasculature. There is a lack of imaging technology for evaluating the microvasculature.
View Article and Find Full Text PDFEffective BCDNet-based breast cancer classification model using hybrid deep learning with VGG16-based optimal feature extraction.
BMC Med Imaging
January 2025
Department of Information Technology, Manipal Institute of Technology Bengaluru, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Problem: Breast cancer is a leading cause of death among women, and early detection is crucial for improving survival rates. The manual breast cancer diagnosis utilizes more time and is subjective. Also, the previous CAD models mostly depend on manmade visual details that are complex to generalize across ultrasound images utilizing distinct techniques.
View Article and Find Full Text PDFMalignant Brenner Tumor of the Ovary: A Critical Reappraisal.
Int J Gynecol Pathol
November 2024
Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia.
Malignant Brenner tumors (MBTs) are rare epithelial tumors of the ovary, most likely arising from benign and borderline Brenner tumors. MBTs may be misdiagnosed as other primary carcinomas or nonepithelial tumors of the ovary as well as metastatic carcinomas. Accurate diagnosis usually requires clinical-radiologic correlation, extensive sampling, and immunohistochemical studies.
View Article and Find Full Text PDFRedefining endoluminal biliary drainage: Challenges and innovations in endosonography-guided techniques.
World J Gastroenterol
January 2025
Department of Gastroenterology and Hepatology, Campus Virchow/Campus Mitte, Charité Berlin, Berlin 10117, Germany.
Endoscopic retrograde cholangiopancreatography is considered the gold standard for treating benign and malignant biliary obstructions. However, its use in complex biliary obstructions is limited. Over the past decades, therapeutic endosonography (EUS) and emerging technologies such as lumen-apposing metal stents have enabled endoscopic treatment of conditions previously requiring non-endoscopic or surgical approaches.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!